973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC

M.C. Garassino, S.M. Gadgeel, G. Speranza, E. Felip, Esther Gonzalez, M. Dómine Gómez, M.J. Hochmair, S.F. Powell, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E.B. Garon, T. Kurata, J.E. Gray, P.O. Schwarzenberger, E. Jensen, D. Rodriguez Abreu